Title : Results of Ivosidenib (inhibitor of mutant IDH1) for nonenhancing IDH1 mutant gliomas
link : Results of Ivosidenib (inhibitor of mutant IDH1) for nonenhancing IDH1 mutant gliomas
Results of Ivosidenib (inhibitor of mutant IDH1) for nonenhancing IDH1 mutant gliomas
Just published in the Journal of Clinical OncologyIvosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
https://sci-hub.tw/10.1200/JCO.19.03327
- out of 35 patients with nonenhancing glioma, objective response rate was 2.9% with one partial response
- of these same patients, 30/35 (85.7%) had stabilization of their disease.
- for these same 35 patients, median progression-free survival was 13.6 months.
- the drug was well-tolerated with no dose-limiting toxicities reported.
As seen here, many of the patients with non-enhancing glioma have had disease stabilization for three years or more. Not bad for a drug that is so well tolerated and with no dose-limited toxicities.
Thus Article Results of Ivosidenib (inhibitor of mutant IDH1) for nonenhancing IDH1 mutant gliomas
That's an article Results of Ivosidenib (inhibitor of mutant IDH1) for nonenhancing IDH1 mutant gliomas This time, hopefully can give benefits to all of you. well, see you in posting other articles.
You are now reading the article Results of Ivosidenib (inhibitor of mutant IDH1) for nonenhancing IDH1 mutant gliomas with the link address https://polennews.blogspot.com/2020/06/results-of-ivosidenib-inhibitor-of.html
0 Response to "Results of Ivosidenib (inhibitor of mutant IDH1) for nonenhancing IDH1 mutant gliomas"
Post a Comment